docetaxel + zoledronic acid

This is a combination therapy consisting of two drugs: - **Docetaxel** is a taxane-class chemotherapeutic agent that inhibits cell division by stabilizing microtubules, thereby preventing their depolymerization. It is primarily used as an antineoplastic agent in various cancers. - **Zoledronic acid** is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. It is used to prevent skeletal-related events (SREs) in patients with bone metastases and has demonstrated some direct antitumor effects. The combination has been studied for potential additive or synergistic effects in cancer treatment, particularly for advanced prostate cancer and non-small-cell lung cancer (NSCLC) with bone metastases. Clinical trials have evaluated this regimen for its impact on survival, progression-free survival, and reduction of skeletal-related events[1][2][3].

Other names

docetaxel + zoledronicdocetaxel plus zoledronic aciddocetaxel and zoledronic acid